Cancers 2013, 5, 1469-1484; doi:10.3390/cancers5041469

Review

Tumor Metabolism of Malignant Gliomas

Peng Ru, Terence M. Williams, Arnab Chakravarti and Deliang Guo *

Department of Radiation Oncology, Ohio State University Comprehensive Cancer Center & Arthur G James Cancer Hospital, Columbus, OH 43012, USA; E-Mails: peng.ru@osumc.edu (P.R.); terence.williams@osumc.edu, (T.M.W.); arnab.chakravarti@osumc.edu (A.C.)

* Author to whom correspondence should be addressed; E-Mail: deliang.guo@osumc.edu; Tel.: +1-614-366-3774; Fax: +1-614-247-1877.

Received: 22 October 2013 / Accepted: 24 October 2013 / Published: 8 November 2013

Abstract: Constitutively activated oncogenic signaling via genetic mutations such as in the EGFR/PI3K/Akt and Ras/RAF/MEK pathways has been recognized as a major driver for tumorigenesis in most cancers. Recent insights into tumor metabolism have further revealed that oncogenic signaling pathways directly promote metabolic reprogramming to upregulate biosynthesis of lipids, carbohydrates, protein, DNA and RNA, leading to enhanced growth of human tumors. Therefore, targeting cell metabolism has become a novel direction for drug development in oncology. In malignant gliomas, metabolism pathways of glucose, glutamine and lipid are significantly reprogrammed. Moreover, molecular mechanisms causing these metabolic changes are just starting to be unraveled. In this review, we will summarize recent studies revealing critical gene alterations that lead to metabolic changes in malignant gliomas, and also discuss promising therapeutic strategies via targeting the key players in metabolic regulation.

Keywords: glioblastoma; tumor metabolism; SREBP-1; LDLR; LXR; glucose; lipids; cholesterol

1. Introduction

Malignant glioblastomas (GBM) are aggressive brain tumors, which are resistant to radiation and chemotherapy [1–4]. In the last decade, targeted inhibition of oncogenic signaling pathways such as EGFR [5–9], PI3K/Akt [10–13], and VEGF [14] has made some progress. However, in patients with malignant glioma, these treatments only show a transient effect and tumor cells quickly develop...
resistance [15,16]. Therefore, in order to significantly improve patient survival, it is necessary to fully understand the biology of malignant gliomas.

In recent years, the understanding of the regulation of tumor metabolism has significantly improved. Accumulating evidence show that tumor cells reprogram their metabolism to meet high energy demands, coordinate markedly elevated biosynthetic processes and energy production, which in turn promote rapid growth and division of tumor cells [17–20]. Thus, targeting metabolism has become a novel promising strategy for treating cancers. Recently, enhanced glycolysis [21,22], elevated glutaminolysis [10,23], and exacerbated lipogenesis have been demonstrated as prominent characteristics in glioblastoma (GBM) [24–29]. There are several important regulators of metabolic pathways, such as Hexokinase 2 (HK2), PKM2 [30,31], IDH1 [32], SREBP-1 and LDLR [24,25,28,29], that have been revealed to be upregulated in GBM. EGFR/PI3K/Akt signaling has been shown to be involved in the regulation of lipid metabolism in GBM [24,25,28,29] (Figure 1). Targeting SREBP-1, a key regulator in lipid metabolism (Figure 1), significantly inhibited tumor cell growth in GBM cell lines and xenograft models [28,33].

In this review, we will focus on the basic metabolism pathways in GBM including glucose, glutamine, and lipid metabolism, and we will discuss the reprogramming of metabolic pathways and the molecular link between oncogenic signaling pathways and key metabolic regulators.

2. Glucose Metabolism in GBM

In normal tissues, ATP is primarily generated in mitochondria via complete oxidative phosphorylation (OXPHOS) of glucose. Conversely, only 10% of ATP is generated from glycolysis in which glucose is converted to lactate [34]. Intriguingly, tumor tissues demonstrate high levels of glycolysis even under aerobic conditions, which is upregulated by PI3K/Akt signaling, known as the Warburg effect [35–40] (Figure 1). In malignant gliomas, aerobic glycolysis is one of the major characteristics of these tumors [21,41]. A number of metabolic enzymes, such as HK2, PKM2 and IDH, play a crucial role in glucose metabolism, and serve as attractive molecular targets.

2.1. Hexokinase II

Hexokinase (HK) functions in the first step of glycolysis and irreversibly catalyzes the phosphorylation of glucose to glucose-6 phosphate (G6P) [42] (Figure 1). Hexokinase has four isoforms referred as type I, II, III and IV which are identified from different mammalian tissues [43]. The type I, II and III HKs have molecular weight at approximately 100 kilodaltons (KD) and can be inhibited by their product G6P. Type IV HK, also known as glucokinase (GK), displays different kinetics from other HK isoforms with a molecular weight of 50 KD [44,45]. In GBM, HK2 is highly expressed, whereas HK1 is predominantly expressed in normal brain and low-grade gliomas [46]. Interestingly, HK2 is expressed in lower levels in the neural subtype, but at higher levels in mesenchymal subtype of GBM [46,47]. In addition, increased HK2 gene expression is correlated with poor overall survival in GBM patients [46,48]. Overexpression of HK2 in GBM promotes tumor cells proliferation, and enhances their resistance to radiation and temozolomide treatment. In contrast, knockdown of HK2 but not HK1 decreases cell proliferation and enhances therapeutic sensitivity in GBM cell line and xenograft models [46].
Figure 1. Regulation of metabolism in malignant gliomas. EGFR signaling upregulates glycolysis and is mediated by PI3K/Akt signaling through inducing GLUT1 translocation to the cell membrane as well as activation of HK2 and PFK. EGFR signaling also upregulates PKM2 expression via activation of the PKCε/NF-κB signaling pathway. Large amounts of lactate are generated even in abundant oxygen conditions. In addition to oxidative phosphorylation, glucose is converted to fatty acids through generation of citrate in the mitochondria, which is in turn released into the cytoplasm and lysed by ACLY to generate the fatty acid precursor acetyl-CoA. Acetyl-CoA is then used for palmitate synthesis and is regulated by ACC and FAS. SCD1 further catalyzes saturated fatty acids to monounsaturated fatty acids. Together they form phospholipids for membrane formation and promote tumor growth. EGFR/PI3K/Akt signaling also activates SREBP-1, which upregulates ACC, FAS and SCD1, to promote de novo fatty acid synthesis. Furthermore, glutamine enters into the TCA cycle to generate energy and also can be converted to lipids through reductive carboxylation under hypoxic conditions. GLUT, glucose transporter; HK2, hexokinase 2; PFK, phosphofructokinase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; PGAM, phosphoglycerate mutase; PEP, phosphoenolpyruvic acid; PKM2, pyruvate kinase M2; LDH, lactate dehydrogenase; PDH, pyruvate dehydrogenase; TCA cycle, tricarboxylic acid cycle; ACLY, ATP citrate lyase; ACC, acetyl-CoA carboxylase; FAS, fatty acid synthase; GLS, glutaminase; EGFR, epidermal growth factor receptor; SREBP-1, sterol regulatory element-binding protein 1.

2.2. PKM2

PKM2 is the M2 isoform of pyruvate kinase (PK) [49]. PK functions in the last step of glycolysis, catalyzing phosphoenolpyruvate (PEP) to pyruvate and generating ATP [49]. Four PK isoforms are identified and derived from two genes, PKLR and PKM in mammals. R and L isoforms are derived from PKLR, expressed in erythrocytes and the liver [49]. M1 and M2 isoforms of PK are produced by alternative splicing of PKM gene, PKM1 contains exon 9 and PKM2 contains exon 10, respectively [50].
Exon 9 and 10 of PKM show different properties, which results in the different activity of PKM1 and PKM2. PKM1 is constitutively active, but PKM2 can be regulated by fructose-1,6-bisphosphate. Recently, splicing repressors of hnRNP A1, hnRNP A2 (heterogeneous nuclear ribonucleoprotein, hnRNP) and PTB (polypyrimidine tract binding protein) were reported to directly bind to the flanking intron of exon 9 and repress the use of exon 9. Downregulation of these splicing repressors increased PKM1 expression levels in cancer cells [48].

PKM2 is mainly expressed in proliferating cells and tissues. In cancer, PKM2, not PKM1, is the major isoform expressed [49,51,52]. Recently, PKM2 has been revealed to be involved in the EGFR signaling pathway in GBM [31,53–55] (Figure 1). PKM2 was shown to translocate into the nucleus from the cytoplasm when activated by EGFR [55]. PKM2, not PKM1, is phosphorylated at Ser37 by ERK1/2 after EGF stimulation. The phosphorylated PKM2 recruits protein interacting with NIMA (Never in Mitosis A)-1 (PIN1) and binds to importin α5, which results in the translocation of PKM2 from cytoplasm to the nucleus. After entering into the nucleus, PKM2 phosphorylates histone 3 at T7 site and also acts as a co-activator of β-catenin to then promote the transcription of CCND1 and MYC. C-Myc further upregulates glucose transporter (GLUT) and HK2 to promote glycolysis (Figure 2) [54]. Interestingly, GLUT3 has been shown to be highly express in gliomas correlated with tumors grade [56,57]. Moreover, in GBM cells, EGFR signaling was shown to also upregulate the expression of PKM2. Activation of EGFR by EGF induces PKCe monoubiquitylation, which then recruits and phosphorylates IKKB, to further promote the interaction of activated RelA/p50 with HIF1α. This complex then binds to the promoter of PKM2 and promotes its transcription (Figure 2) [31]. Recently, miR-326 has been reported to inhibit GBM by directly targeting PKM2 [30]. Taken together, these data demonstrated the novel roles for PKM2 in GBM beyond its traditional roles in glycolysis.

**Figure 2.** EGFR signaling regulation of PKM2 in gliomas. EGFR signaling promotes PKM2 translocation to nucleus after phosphorylation by ERK. PKM2 then phosphorylates histone H3-T11 and binds to β-catenin to promote MYC expression. MYC stimulates GLUT1 and LDH expression to further promote glycolysis. Moreover, EGFR signaling upregulates PKM2 expression, which is mediated by PKCe/NF-κB activation and interaction with HIF1α.
2.3. IDH

Isocitrate dehydrogenase (IDH) is an enzyme that catalyzes the oxidative decarboxylation of isocitrate to produce $\alpha$-ketoglutarate, and also generate NADH in mitochondria or NADPH in cytoplasm [58]. In the human genome, 5 IDH genes have been identified: two of them produce IDH1 and IDH2, which form homodimers; the other 3 genes produce IDH3 ($\text{IDH3}_\alpha$, $\text{IDH3}_\beta$, and $\text{IDH3}_\gamma$), which form heterotetrameric proteins [59]. IDH1 is located in the cytoplasm and peroxisomes, but IDH2 and IDH3 are localized in the mitochondria [59].

In 2008, IDH1 and IDH2 mutations were first reported in low grade of gliomas and secondary GBM [60–62]. IDH1 mutation is described in more than 70% and 50% of grade II and III glioma tumors [63], but only 5% in primary GBM [64]. In addition, IDH1 mutations occur approximately in 80% and 85% of diffuse astrocytomas and secondary GBMs, respectively [59]. IDH1/2 mutation often co-occurs with the deletion of 1p19q and mutation of p53 [64,65]. IDH1 and IDH2 mutation results in reduced enzymatic ability and therefore reduces the production of $\alpha$-KG [66]. $\alpha$-KG is required by propyl hydroxylases (PHD) for degradation of hypoxia-induced factor-1$\alpha$ (HIF-1$\alpha$) [67]. Therefore, IDH1 is involved in the HIF-1$\alpha$ signaling pathway, which is critical for tumor progression, glucose metabolism, angiogenesis, and invasion under low oxygen levels [68]. Surprisingly, IDH1/2 mutants gain new enzyme activity, which catalyzes $\alpha$-KG to 2-hydroxyglutarate (2-HG), a metabolite produced mostly in error in normal metabolism where it is usually present in low levels [58,69–71]. In glioma patients, IDH mutations are associated with elevated 2-HG levels [69–72].

Recently, CpG island methylation profiling was performed to identify the difference between IDH1-R132 mutant and IDH1-R132 wild type GBM. The profiling analysis showed a similar methylation pattern in IDH1-R132 mutant GBM and a newly-described CpG island methylator phenotype (CIMP) [73]. The phenotypes of induction of extensive DNA hypermethylation with inhibition of histone demethylation were observed when the mutant IDH1 was introduced into primary human astrocytes. These data demonstrate that the mutation of IDH1 is sufficient to remodel the methylome in glioma and establish CIMP [74]. IDH mutation also reduces histone demethylation and inhibits differentiation of non-transformed astrocyte cells [75]. The expression of lineage-specific differentiation genes is inhibited by the introduction of mutant IDH1 or cell-permeable 2-HG [75]. The accumulation of histone methylation is observed with the introduction of 2-HG-producing mutant IDH into immortalized astrocytes [75]. In summary, these data strongly reveal that IDH mutations are clearly involved in the regulation of differentiation of non-transformed cells.

3. Glutamine Metabolism

In addition to glucose, glutamine is another major energy source for cells [76,77] (Figure 1). Glutamine also is a nitrogen donor for tumor cells [78]. Recently, glutamine metabolism has been reported to be highly upregulated in cancers [17,79–82]. Elevated expression of glutaminase (GLS) is found in tumors and rapidly proliferating cells [83] (Figure 1). GLS, located in the mitochondria, catalyzes the conversion of glutamine to glutamate, and is upregulated by the oncogene c-Myc [84,85]. NF-$\kappa$B-dependent upregulation of glutaminase by oncogene Rho GTPase has also been described whereas blocking Rho GTPase leads to the inhibition of cancer growth [86]. Nuclear magnetic
resonance (NMR) spectroscopy shows that glutamine concentration (3.4 ± 0.9 mmol/L) was significantly higher in GBM patients than in control subjects (2.7 ± 0.7 mmol/L; p = 0.01) [87]. Interestingly, lower expression of glutamine synthetase (GS), which catalyzes glutamate to glutamine correlates with better survival of patients with GBM [88]. Compared to our knowledge of glucose metabolism in cancers, glutamine metabolism in GBM is much less known. Thus significant investigations are needed to reveal the function of glutamine metabolism in GBM tumorigenesis and resistance to therapies.

4. Lipid Metabolism in GBM

Lipids consist of phospholipids, fatty acid, cholesterol, triglycerides, cholesterol esters, sphingolipids and others, which are critical components to form cellular membranes [89–93]. In addition to their role as structural components, lipids also function as energy resources and as signaling molecules to maintain cell growth [25,94,95].

Lipid metabolism has been found to be largely altered in cancers [96–99], and exacerbated lipogenesis has been shown to be a prominent characteristic in most cancers [25,94,100]. In GBM, tumor tissues contain higher levels of unsaturated fatty acids compared with normal brain [101]. Recent studies have revealed intrinsic molecular alterations in lipid metabolism. Key genes that regulate lipid metabolism, such as SREBP-1 and its downstream-targeted genes Acetyl-CoA carboxylase (ACC), Fatty acid synthase (FAS) and low-density lipoprotein receptor (LDLR), are upregulated in GBMs [27–29] (Figures 1 and 3). Intriguingly, the oncogenic signaling pathway EGFR/PI3K/Akt has been shown to regulate this metabolic reprogramming [27–29] (Figures 1 and 3).

4.1. SREBP-1

Sterol regulatory element-binding proteins (SREBPs) are important transcription factors that regulate lipid metabolism thereby playing a crucial role in the regulation of lipogenesis and cholesterol uptake [102]. There are three SREBP isoforms, namely SREBP-1a, -1c and -2 [102]. SREBP-1 (-1a and -1c) regulates fatty acid synthesis [103] while SREBP-2 regulates cholesterol synthesis [104]. The transcriptional activity of SREBPs is tightly regulated by cellular sterol levels via post-translational regulation. Moreover, the full length SREBP-1 or -2 proteins have no activity. Indeed, these proteins bind to SREBP cleavage-activating protein (SCAP) and are retained by Insig protein on the membrane of the endoplasmic reticulum (ER) when sterol levels are high [105]. However, when sterol levels decrease, SCAP will dissociate from Insig and then carry SREBPs to the Golgi [105]. Upon translocation to the Golgi, the N-terminus of SREBPs will be released from the membrane after sequential cleavage by the membrane-bound serine proteases, S1P and S2P [106,107]. Then, only the N-terminus enters into the nucleus to promote its downstream gene expression [104,108,109].

Interestingly, SREBP-1 has been found to be highly activated in GBM and other cancers [28,110–113]. Its nuclear form is abundantly present in GBM patient tissues, which is accompanied with the high expression of its downstream genes ACC and FAS, the key genes regulating de novo fatty acid synthesis [28] (Figure 1). Moreover, genetically or pharmaceutically inhibition of SREBP1, ACC or FAS in GBM has been shown to significantly induce cell death, suggesting that SREBP1 is a promising therapeutic target in GBM [28]. More recently, inhibition of SREBP-1 has been shown to markedly
reduce the levels of unsaturated fatty acids by downregulating stearoyl-CoA desaturase 1 (SCD1), a key enzyme to catalyze saturated fatty acid to mono-unsaturated fatty acid (Figure 1), thus increasing the ratio of saturated- to unsaturated-fatty acids and leading to lipotoxicity in GBM cells [33,114].

In addition to the feedback regulation by sterol levels, SREBP-1 is highly upregulated by receptor tyrosine kinases (RTKs)/PI3K/Akt signaling in GBM [28] (Figure 1). More interestingly, inhibiting SREBP-1 and its downstream genes ACC and FAS has been shown to markedly induce cell death in GBM cells, particularly in cells with high levels of EGFR signaling [28,33]. These data demonstrate that GBM cells with activated RTK signaling are dependent on the SREBP-1-regulated de novo fatty acid synthesis pathway for survival and malignant growth.

4.2. LDLR

Cholesterol is also an important component of cell membranes [90,115]. In cells, extra cholesterol will be esterified with fatty acids to form cholesterol esters which are then stored within the cells [116]. Using NMR technique, cholesterol esters have been found to be abundantly present in tumor tissues in high grade gliomas, human urothelial carcinoma, and malignant renal cell carcinomas, but undetectable in normal tissues [116–120]. These findings demonstrate that cholesterol metabolism is also altered in these cancers. But the molecular mechanism underlying this alteration is largely unknown.

Recently, low density lipoprotein receptor (LDLR) has been found to be upregulated in GBM patient tissues, xenograft tumors and cell lines, and this upregulation is correlated with high levels of cholesterol esters in GBM cells [29,121]. The function of LDLR is to bind low-density lipoprotein (LDL), the major cholesterol found in abundance within the bloodstream, and then bring LDL into cells and provide cholesterol for cell utilization [122]. Its upregulation could partially explain the accumulation of cholesterol esters in GBM. Interestingly, LDLR has been shown to also be upregulated by EGFR/PI3K/Akt signaling, which was been shown to be mediated by SREBP-1, but not SREBP-2 in GBM cells [29] (Figure 3).

4.3. LXR/ABCA1

Cholesterol homeostasis is regulated by uptake, de novo synthesis, and efflux (Figure 3). When cellular cholesterol level increases, it will be oxygenized to oxidized sterol and then activates liver X receptor (LXR), a transcriptional factor that controls expression of cholesterol efflux genes, such as ATP-binding cassette protein A1 (ABCA1) and G1 (ABCG1) [123]. ABCA1 and ABCG1 promote reverse transport of cholesterol outside of cells, thus reducing cellular cholesterol levels [124] (Figure 3). Interestingly, activation of LXR by its agonists GW3965 and T0901317 has been shown to significantly inhibit tumor growth in GBM, breast, and prostate cancers [24,25,29,125]. Additionally, activation of LXR by GW3965 downregulates LDLR levels through upregulating a ubiquitin ligase E3 known as inducible degrader of LDLR (Idol), which leads to LDLR degradation [29,126] (Figure 3). Therefore, activation of LXR could be a potential therapeutic strategy to inhibit GBM growth through increasing cholesterol efflux as well as decreasing its uptake.
Figure 3. Regulation of cholesterol metabolism in gliomas. Cholesterol homeostasis is regulated by uptake, synthesis and efflux. EGFR/PI3K/Akt signaling upregulates LDLR expression mediated by SREBP-1 to promote cholesterol uptake. Activation of LXR stimulates ABCA1 expression and promotes cholesterol efflux, but also reduces LDLR levels via upregulation of Inducible Degrader of LDLR (Idol), a ubiquitin ligase E3. LXR, liver X receptor; ABCA1, ATP-binding cassette transporter member 1; LDL, low density lipoprotein; LDLR, LDL receptor.

5. Conclusions

Metabolic reprogramming is a key feature driving oncogenesis in cancers. Recent studies have revealed that glucose, glutamine and lipid metabolism are largely altered in GBM and facilitate its malignant growth. Oncogenic signaling pathways are found to regulate these metabolic alterations. Targeting metabolic reprogramming is a novel and promising therapeutic strategy to treat cancers. Further understanding of the metabolic alterations in GBM will definitely shed light on developing effective approaches to abrogate GBM malignant growth, and also provide insights to overcome GBM resistance with current therapies.

Acknowledgements

This work was supported by Rose DiGangi American Brain Tumor Association Translational Grant (DG) and NIH/NINDS NS072838 (DG) and NS079701 (DG).

Conflicts of Interest

The authors declare no conflict of interest.
References

1. Kaplan, R.S. Supratentorial malignant gliomas: Risk patterns and therapy. J. Natl. Cancer. Inst. 1993, 85, 690–691.
2. Furnari, F.B.; Fenton, T.; Bachoo, R.M.; Mukasa, A.; Stommel, J.M.; Stegh, A.; Hahn, W.C.; Ligon, K.L.; Louis, D.N.; Brennan, C.; et al. Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes. Dev. 2007, 21, 2683–2710.
3. Wen, P.Y.; Kesari, S. Malignant gliomas in adults. N. Engl. J. Med. 2008, 359, 492–507.
4. Dunn, G.P.; Rinne, M.L.; Wykosky, J.; Genovese, G.; Quayle, S.N.; Dunn, I.F.; Agarwalla, P.K.; Chheda, M.G.; Campos, B.; Wang, A.; et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 2012, 26, 756–784.
5. Seshacharyulu, P.; Ponnusamy, M.P.; Haridas, D.; Jain, M.; Ganti, A.K.; Batra, S.K. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin. Ther. Targets 2012, 16, 15–31.
6. Mellinghoff, I.K.; Wang, M.Y.; Vivanco, I.; Haas-Kogan, D.A.; Zhu, S.; Dia, E.Q.; Lu, K.V.; Yoshimoto, K.; Huang, J.H.; Clute, D.J.; et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 2005, 353, 2022–2024.
7. Wheeler, D.L.; Dunn, E.F.; Harari, P.M. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat. Rev. Clin. Oncol. 2010, 7, 493–507.
8. Chakravarti, A.; Wang, M.; Robins, H.I.; Lautenschlaeger, T.; Curran, W.J.; Brachman, D.G.; Schultz, C.J.; Choucair, A.; Dolled-Filhart, M.; Christiansen, J.; et al. RTOG 0211: A phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int. J. Radiat. Oncol. Biol. Phys. 2013, 85, 1206–1211.
9. Tanaka, K.; Babic, I.; Nathanson, D.; Akhavan, D.; Guo, D.; Gini, B.; Dang, J.; Zhu, S.; Yang, H.; de Jesus, J.; et al. Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance. Cancer Discov. 2011, 1, 524–538.
10. Marin-Valencia, I.; Yang, C.; Mashimo, T.; Cho, S.; Baek, H.; Yang, X.L.; Rajagopalan, K.N.; Maddie, M.; Vemireddy, V.; Zhao, Z.; et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 2012, 15, 827–837.
11. Martini, M.; Cirao, E.; Gulluni, F.; Hirsch, E. Targeting PI3K in Cancer: Any Good News? Front. Oncol. 2013, 3, 108.
12. Courtney, K.D.; Corcoran, R.B.; Engelman, J.A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 2010, 28, 1075–1083.
13. Chakravarti, A.; Zhai, G.; Suzuki, Y.; Sarkesh, S.; Black, P.M.; Muzikansky, A.; Loeffler, J.S. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J. Clin. Oncol. 2004, 22, 1926–1933.
14. Ferrara, N. VEGF as a therapeutic target in cancer. Oncology 2005, 69, 11–16.
15. Jun, H.J.; Acquaviva, J.; Chi, D.; Lessard, J.; Zhu, H.; Woolfenden, S.; Bronson, R.T.; Pfannl, R.; White, F.; Housman, D.E.; et al. Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme. Oncogene 2012, 31, 3039–3050.
16. Huang, T.T.; Sarkaria, S.M.; Cloughesy, T.F.; Mischel, P.S. Targeted therapy for malignant glioma patients: Lessons learned and the road ahead. Neurotherapeutics 2009, 6, 500–512.
17. DeBerardinis, R.J.; Lum, J.J.; Hatzivassiliou, G.; Thompson, C.B. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. *Cell Metab.* 2008, 7, 11–20.
18. Deberardinis, R.J.; Thompson, C.B. Cellular metabolism and disease: What do metabolic outliers teach us? *Cell* 2012, 148, 1132–1144.
19. Vander Heiden, M.G.; Cantley, L.C.; Thompson, C.B. Understanding the Warburg effect: The metabolic requirements of cell proliferation. *Science* 2009, 324, 1029–1033.
20. Schulze, A.; Harris, A.L. How cancer metabolism is tuned for proliferation and vulnerable to disruption. *Nature* 2012, 491, 364–373.
21. Wolf, A.; Agnihotri, S.; Guha, A. Targeting metabolic remodeling in glioblastoma multiforme. *Oncotarget* 2010, 1, 552–562.
22. Maher, E.A.; Marin-Valencia, I.; Bachoo, R.M.; Mashimo, T.; Raisanen, J.; Hatanpaa, K.J.; Jindal, A.; Jeffrey, F.M.; Choi, C.; Madden, C.; et al. Metabolism of [U-(13) C]glucose in human brain tumors *in vivo*. *NMR Biomed.* 2012, 25, 1234–1244.
23. Yang, C.; Sudderth, J.; Dang, T.; Bachoo, R.M.; McDonald, J.G.; DeBerardinis, R.J. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. *Cancer Res.* 2009, 69, 7986–7993.
24. Bell, E.H.; Guo, D. Biomarkers for malignant gliomas. *Malig. Gliomas Radiat. Med. Rounds* 2012, 3, 389–357.
25. Guo, D.; Bell, E.H.; Chakravarti, A. Lipid metabolism emerges as a promising target for malignant glioma therapy. *CNS Oncol.* 2013, 2, 289–299.
26. Guo, D.; Cloughesy, T.F.; Radu, C.G.; Mischel, P.S. AMPK: A metabolic checkpoint that regulates the growth of EGFR activated glioblastomas. *Cell Cycle* 2010, 9, 211–212.
27. Guo, D.; Hildebrandt, I.J.; Prins, R.M.; Soto, H.; Mazzotta, M.M.; Dang, J.; Czernin, J.; Shyy, J.Y.; Watson, A.D.; Phelps, M.; et al. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. *Proc. Natl. Acad. Sci. USA* 2009, 106, 12932–12937.
28. Kefas, B.; Comeau, L.; Erdle, N.; Montgomery, E.; Amos, S.; Purow, B. Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. *Neuro. Oncol.* 2010, 12, 1102–1112.
29. Yang, W.; Xia, Y.; Cao, Y.; Zheng, Y.; Bu, W.; Zhang, L.; You, M.J.; Koh, M.Y.; Cote, G.; Aldape, K.; et al. EGFR-induced and PKCepsilon monoubiquitylation-dependent NF-kappaB activation upregulates PKM2 expression and promotes tumorigenesis. *Mol. Cell* 2012, 48, 771–784.
30. Dang, L.; Jin, S.; Su, S.M. IDH mutations in glioma and acute myeloid leukemia. *Trends Mol. Med.* 2010, 16, 387–397.
33. Williams, K.J.; Argus, J.P.; Zhu, Y.; Wilks, M.Q.; Marbois, B.N.; York, A.G.; Kidani, Y.; Pourzia, A.L.; Akhavan, D.; Lisiero, D.N.; et al. An Essential Requirement for the SCAP/SREBP Signaling Axis to Protect Cancer Cells from Lipotoxicity. *Cancer Res.** 2013, **73**, 2850–2862.

34. Ainscow, E.K.; Brand, M.D. Top-down control analysis of ATP turnover, glycolysis and oxidative phosphorylation in rat hepatocytes. *Eur. J. Biochem.** 1999, **263**, 671–685.

35. Lopez-Lazaro, M. The warburg effect: Why and how do cancer cells activate glycolysis in the presence of oxygen? *Anticancer Agents Med Chem.** 2008, **8**, 305–312.

36. Warburg, O. On the origin of cancer cells. *Science** 1956, **123**, 309–314.

37. Warburg, O. On respiratory impairment in cancer cells. *Science** 1956, **124**, 269–270.

38. Ward, P.S.; Thompson, C.B. Metabolic reprogramming: A cancer hallmark even warburg did not anticipate. *Cancer Cell** 2012, **21**, 297–308.

39. Koppenol, W.H.; Bounds, P.L.; Dang, C.V. Otto Warburg's contributions to current concepts of cancer metabolism. *Nat. Rev. Cancer** 2011, **11**, 325–337.

40. Lunt, S.Y.; Vander Heiden, M.G. Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation. *Annu. Rev. Cell. Dev. Biol.** 2011, **27**, 441–464.

41. Babic, I.; Anderson, E.S.; Tanaka, K.; Guo, D.; Masui, K.; Li, B.; Zhu, S.; Gu, Y.; Villa, G.R.; Akhavan, D.; et al. EGFR Mutation-Induced Alternative Splicing of Max Contributes to Growth of Glycolytic Tumors in Brain Cancer. *Cell Metab.** 2013, **17**, 1000–1008.

42. Kim, J.W.; Dang, C.V. Multifaceted roles of glycolytic enzymes. *Trends Biochem. Sci.** 2005, **30**, 142–150.

43. Wilson, J.E. Isozymes of mammalian hexokinase: Structure, subcellular localization and metabolic function. *J. Exp. Biol.** 2003, **206**, 2049–2057.

44. Postic, C.; Shiota, M.; Magnuson, M.A. Cell-specific roles of glucokinase in glucose homeostasis. *Recent Prog. Horm. Res.** 2001, **56**, 51–66.

45. Printz, R.L.; Magnuson, M.A.; Granner, D.K. Mammalian glucokinase. *Annu. Rev. Nutr.** 1993, **13**, 463–496.

46. Wolf, A.; Agnihotri, S.; Micallef, J.; Mukherjee, J.; Sabha, N.; Cairns, R.; Hawkins, C.; Guha, A. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. *J. Exp. Med.** 2011, **208**, 313–326.

47. Agnihotri, S.; Wolf, A.; Munoz, D.M.; Smith, C.J.; Gajadhar, A.; Restrepo, A.; Clarke, I.D.; Fuller, G.N.; Kesari, S.; Dirks, P.B.; et al. A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. *J. Exp. Med.** 2011, **208**, 689–702.

48. Wolf, A.; Agnihotri, S.; Munoz, D.; Guha, A. Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme. *Neurobiol. Dis.** 2011, **44**, 84–91.

49. Mazurek, S.; Boschek, C.B.; Hugo, F.; Eigenbrodt, E. Pyruvate kinase type M2 and its role in tumor growth and spreading. *Semin Cancer Biol.** 2005, **15**, 300–308.

50. Clower, C.V.; Chatterjee, D.; Wang, Z.; Cantley, L.C.; Vander Heiden, M.G.; Krainer, A.R. The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. *Proc. Natl. Acad. Sci. USA** 2010, **107**, 1894–1899.

51. Mazurek, S. Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells. *Int. J. Biochem. Cell Biol.** 2011, **43**, 969–980.
52. Christofk, H.R.; Vander Heiden, M.G.; Harris, M.H.; Ramanathan, A.; Gerszten, R.E.; Wei, R.; Fleming, M.D.; Schreiber, S.L.; Cantley, L.C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. *Nature 2008*, 452, 230–233.

53. Yang, W.; Xia, Y.; Hawke, D.; Li, X.; Liang, J.; Xing, D.; Aldape, K.; Hunter, T.; Alfred Yung, W.K.; Lu, Z. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. *Cell 2012*, 150, 1295–1304.

54. Liu, Y.; Li, Y.M.; Tian, R.F.; Liu, W.P.; Fei, Z.; Long, Q.F.; Wang, X.A.; Zhang, X. The expression and significance of HIF-1alpha and GLUT-3 in glioma. *Brain Res. 2009*, 1304, 149–154.

55. Boado, R.J.; Black, K.L.; Pardridge, W.M. Gene expression of GLUT3 and GLUT1 glucose transporters in human brain tumors. *Brain Res. Mol. Brain Res. 1994*, 27, 51–57.

56. Reitman, Z.J.; Yan, H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: Alterations at a crossroads of cellular metabolism. *J. Natl. Cancer Inst. 2010*, 102, 932–941.

57. Yan, H.; Parsons, D.W.; Jin, G.; McLendon, R.; Rasheed, B.A.; Yuan, W.; Kos, I.; Batinic-Haberle, I.; Jones, S.; Riggins, G.J.; et al. IDH1 and IDH2 mutations in gliomas. *N. Engl. J. Med. 2009*, 360, 765–773.

58. DeAngelis, L.M.; Mellinghoff, I.K. Virchow 2011 or how to ID(H) human glioblastoma. *J. Clin. Oncol. 2011*, 29, 4473–4474.

59. Watanabe, T.; Nobusawa, S.; Kleihues, P.; Ohgaki, H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. *Am. J. Pathol. 2009*, 174, 1149–1153.

60. Riemen Schneider, M.J.; Jeuken, J.W.; Wesseling, P.; Reifenberger, G. Molecular diagnostics of gliomas: State of the art. *Acta Neuropathol. 2010*, 120, 567–584.

61. Ward, P.S.; Patel, J.; Wise, D.R.; Abdel-Wahab, O.; Bennett, B.D.; Coller, H.A.; Cross, J.R.; Fantin, V.R.; Hedvat, C.V.; Perl, A.E.; et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. *Cancer Cell 2010*, 17, 225–234.

62. Boulahbel, H.; Duran, R.V.; Gottlieb, E. Prolyl hydroxylases as regulators of cell metabolism. *Biochem. Soc. Trans. 2009*, 37, 291–294.
68. Zhao, S.; Lin, Y.; Xu, W.; Jiang, W.; Zha, Z.; Wang, P.; Yu, W.; Li, Z.; Gong, L.; Peng, Y.; et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009, 324, 261–265.

69. Andronesi, O.C.; Kim, G.S.; Gerstner, E.; Batchelor, T.; Tzika, A.A.; Fantin, V.R.; Vander Heiden, M.G.; Sorensen, A.G. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci. Transl. Med. 2012, 4, 116ra114.

70. Choi, C.; Ganji, S.K.; DeBerardinis, R.J.; Hatanpaa, K.J.; Rakheja, D.; Kovacs, Z.; Yang, X.L.; Mashimo, T.; Raisanen, J.M.; Marin-Valencia, I.; et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat. Med. 2012, 18, 624–629.

71. Kalinina, J.; Carroll, A.; Wang, L.; Yu, Q.; Mancheno, D.E.; Wu, S.; Liu, F.; Ahn, J.; He, M.; Mao, H.; et al. Detection of “oncometabolite” 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma. J. Mol. Med (Berl.) 2012, 90, 1161–1171.

72. Dang, L.; White, D.W.; Gross, S.; Bennett, B.D.; Driggers, E.M.; Fantin, V.R.; Jang, H.G.; Jin, S.; Keenan, M.C.; et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2010, 465, 966.

73. Lai, A.; Kharbanda, S.; Pope, W.B.; Tran, A.; Solis, O.E.; Peale, F.; Forrest, W.F.; Pujara, K.; Carrillo, J.A.; Pandita, A.; et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J. Clin. Oncol. 2011, 29, 4482–4490.

74. Turkcan, S.; Rohle, D.; Goenka, A.; Walsh, L.A.; Fang, F.; Yilmaz, E.; Campos, C.; Fabius, A.W.; Lu, C.; Ward, P.S.; et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012, 483, 479–483.

75. Lu, C.; Ward, P.S.; Kapoor, G.S.; Rohle, D.; Turkcan, S.; Abdel-Wahab, O.; Edwards, C.R.; Khanin, R.; Figueroa, M.E.; Melnick, A.; et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483, 474–478.

76. Zielke, H.R.; Zielke, C.L.; Ozand, P.T. Glutamine: A major energy source for cultured mammalian cells. Fed. Proc. 1984, 43, 121–125.

77. Reitzer, L.J.; Wice, B.M.; Kennell, D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J. Biol. Chem. 1979, 254, 2669–2676.

78. Cory, J.G.; Cory, A.H. Critical roles of glutamine as nitrogen donors in purine and pyrimidine nucleotide synthesis: Asparaginase treatment in childhood acute lymphoblastic leukemia. In vivo 2006, 20, 587–589.

79. Butler, E.B.; Zhao, Y.; Munoz-Pinedo, C.; Lu, J.; Tan, M. Stalling the engine of resistance: Targeting cancer metabolism to overcome therapeutic resistance. Cancer Res. 2013, 73, 2709–2717.

80. DeBerardinis, R.J.; Mancuso, A.; Daikhin, E.; Nissim, I.; Yudkoff, M.; Wehrli, S.; Thompson, C.B. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl. Acad. Sci. USA 2007, 104, 19345–19350.

81. Rajagopalan, K.N.; DeBerardinis, R.J. Role of glutamine in cancer: Therapeutic and imaging implications. J. Nucl. Med. 2011, 52, 1005–1008.

82. Daye, D.; Wellen, K.E. Metabolic reprogramming in cancer: Unraveling the role of glutamine in tumorigenesis. Semin. Cell Dev. Biol. 2012, 23, 362–369.
83. Lu, W.; Pelicano, H.; Huang, P. Cancer metabolism: Is glutamine sweeter than glucose? *Cancer Cell* **2010**, *18*, 199–200.

84. Dang, C.V.; Le, A.; Gao, P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. *Clin. Cancer Res.* **2009**, *15*, 6479–6483.

85. Rathore, M.G.; Saumet, A.; Rossi, J.F.; de Bettignies, C.; Tempe, D.; Lecellier, C.H.; Villalba, M. The NF-kappaB member p65 controls glutamine metabolism through miR-23a. *Int. J. Biochem. Cell Biol.* **2012**, *44*, 1448–1456.

86. Wang, J.B.; Erickson, J.W.; Fuji, R.; Ramachandran, S.; Gao, P.; Dinavahi, R.; Wilson, K.F.; Ambrosio, A.L.; Dias, S.M.; Dang, C.V.; *et al*. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. *Cancer Cell* **2010**, *18*, 207–219.

87. Kallenberg, K.; Bock, H.C.; Helms, G.; Jung, K.; Wrede, A.; Buhk, J.H.; Giese, A.; Frahm, J.; Strik, H.; Dechent, P.; *et al*. Untreated glioblastoma multiforme: Increased myo-inositol and glutamine levels in the contralateral cerebral hemisphere at proton MR spectroscopy. *Radiology* **2009**, *253*, 805–812.

88. Rosati, A.; Marconi, S.; Pollo, B.; Tomassini, A.; Lovato, L.; Maderna, E.; Maier, K.; Schwartz, A.; Rizzuto, N.; Padovani, A.; *et al*. Epilepsy in glioblastoma multiforme: Correlation with glutamine synthetase levels. *J. Neurooncol.* **2009**, *93*, 319–324.

89. Maxfield, F.R. Plasma membrane microdomains. *Curr. Opin. Cell Biol.* **2002**, *14*, 483–487.

90. Mukherjee, S.; Maxfield, F.R. Membrane domains. *Annu. Rev. Cell Dev. Biol.* **2004**, *20*, 839–866.

91. Pomorski, T.; Hrafnsdottir, S.; Devaux, P.F.; van Meer, G. Lipid distribution and transport across cellular membranes. *Semin. Cell Dev. Biol.* **2001**, *12*, 139–148.

92. Van Meer, G. Membranes in motion. *EMBO Rep.* **2010**, *11*, 331–333.

93. Van Meer, G.; Voelker, D.R.; Feigenson, G.W. Membrane lipids: Where they are and how they behave. *Nat. Rev. Mol. Cell Biol.* **2008**, *9*, 112–124.

94. Menendez, J.A.; Lupu, R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. *Nat. Rev. Cancer* **2007**, *7*, 763–777.

95. Zechnner, R.; Strauss, J.G.; Haemmerle, G.; Lass, A.; Zimmermann, R. Lipolysis: Pathway under construction. *Curr. Opin. Lipidol.* **2005**, *16*, 333–340.

96. Abramson, H.N. The lipogenesis pathway as a cancer target. *J. Med. Chem.* **2011**, *54*, 5615–5638.

97. Grossi-Paoletti, E.; Paoletti, P.; Fumagalli, R. Lipids in brain tumors. *J. Neurosurg.* **1971**, *34*, 454–455.

98. Podo, F. Tumour phospholipid metabolism. *NMR Biomed.* **1999**, *12*, 413–439.

99. Santos, C.R.; Schulze, A. Lipid metabolism in cancer. *FEBS J.* **2012**, *279*, 2610–2623.

100. Yoon, S.; Lee, M.Y.; Park, S.W.; Moon, J.S.; Koh, Y.K.; Ahn, Y.H.; Park, B.W.; Kim, K.S. Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells. *J. Biol. Chem.* **2007**, *282*, 26122–26131.

101. Gopal, K.; Grossi, E.; Paoletti, P.; Usardi, M. Lipid composition of human intracranial tumors: A biochemical study. *Acta Neurochir. (Wien)* **1963**, *11*, 333–347.

102. Horton, J.D.; Goldstein, J.L.; Brown, M.S. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. *J. Clin. Invest.* **2002**, *109*, 1125–1131.
103. Shimano, H. Sterol regulatory element-binding proteins (SREBPs): Transcriptional regulators of lipid synthetic genes. *Prog. Lipid Res. 2001*, 40, 439–452.

104. Brown, M.S.; Goldstein, J.L. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. *Cell 1997*, 89, 331–340.

105. Nohturfft, A.; DeBose-Boyd, R.A.; Scheek, S.; Goldstein, J.L.; Brown, M.S. Sterols regulate cycling of SREBP cleavage-activating protein (SCAP) between endoplasmic reticulum and Golgi. *Proc. Natl. Acad. Sci. USA 1999*, 96, 11235–11240.

106. Sakai, J.; Duncan, E.A.; Rawson, R.B.; Hua, X.; Brown, M.S.; Goldstein, J.L. Sterol-regulated release of SREBP-2 from cell membranes requires two sequential cleavages, one within a transmembrane segment. *Cell 1996*, 85, 1037–1046.

107. Zelenski, N.G.; Rawson, R.B.; Brown, M.S.; Goldstein, J.L. Membrane topology of S2P, a protein required for intramembranous cleavage of sterol regulatory element-binding proteins. *J. Biol. Chem. 1999*, 274, 21973–21980.

108. Espenshade, P.J.; Cheng, D.; Goldstein, J.L.; Brown, M.S. Autocatalytic processing of site-1 protease removes propeptide and permits cleavage of sterol regulatory element-binding proteins. *J. Biol. Chem. 1999*, 274, 22795–22804.

109. Hua, X.; Yokoyama, C.; Wu, J.; Briggs, M.R.; Brown, M.S.; Goldstein, J.L.; Wang, X. SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element. *Proc. Natl. Acad. Sci. USA 1993*, 90, 11603–11607.

110. Jeon, T.I.; Osborne, T.F. SREBPs: Metabolic integrators in physiology and metabolism. *Trends Endocrinol. Metab. 2012*, 23, 65–72.

111. Shao, W.; Espenshade, P.J. Expanding Roles for SREBP in Metabolism. *Cell Metab. 2012*, 16, 414–419.

112. Ettinger, S.L.; Sobel, R.; Whitmore, T.G.; Akbari, M.; Bradley, D.R.; Gleave, M.E.; Nelson, C.C. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. *Cancer Res. 2004*, 64, 2212–2221.

113. Yang, Y.; Morin, P.J.; Han, W.F.; Chen, T.; Bornman, D.M.; Gabrielson, E.W.; Pizer, E.S. Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. *Exp. Cell Res. 2003*, 282, 132–137.

114. Von Roemeling, C.A.; Marlow, L.A.; Wei, J.J.; Cooper, S.J.; Caulfield, T.R.; Wu, K.; Tan, W.W.; Tun, H.W.; Copland, J.A. Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma. *Clin. Cancer Res. 2013*, 19, 2368–2380.

115. Maxfield, F.R.; Tabas, I. Role of cholesterol and lipid organization in disease. *Nature 2005*, 438, 612–621.

116. Tosi, M.R.; Tugnoli, V. Cholesteryl esters in malignancy. *Clin. Chim. Acta 2005*, 359, 27–45.

117. Tugnoli, V.; Tosi, M.R. Cholesteryl ester detection in a human urothelial carcinoma. *Clin. Chim. Acta 2005*, 360, 208–210.

118. Tugnoli, V.; Tosi, M.R.; Tinti, A.; Trinchero, A.; Bottura, G.; Fini, G. Characterization of lipids from human brain tissues by multinuclear magnetic resonance spectroscopy. *Biopolymers. 2001*, 62, 297–306.

119. Tugnoli, V.; Bottura, G.; Fini, G.; Reggiani, A.; Tinti, A.; Trinchero, A.; Tosi, M.R. 1H-NMR and 13C-NMR lipid profiles of human renal tissues. *Biopolymers 2003*, 72, 86–95.
120. Yates, A.J.; Thompson, D.K.; Boesel, C.P.; Albrightson, C.; Hart, R.W. Lipid composition of human neural tumors. *J. Lipid Res.* **1979**, *20*, 428–436.
121. Rudling, M.J.; Angelin, B.; Peterson, C.O.; Collins, V.P. Low density lipoprotein receptor activity in human intracranial tumors and its relation to the cholesterol requirement. *Cancer Res.* **1990**, *50*, 483–487.
122. Goldstein, J.L.; Brown, M.S. The LDL receptor. *Arterioscler. Thromb. Vasc. Biol.* **2009**, *29*, 431–438.
123. Zelcer, N.; Tontonoz, P. Liver X receptors as integrators of metabolic and inflammatory signaling. *J. Clin. Invest.* **2006**, *116*, 607–614.
124. Calkin, A.C.; Tontonoz, P. Liver X receptor signaling pathways and atherosclerosis. *Arterioscler. Thromb. Vasc. Biol.* **2010**, *30*, 1513–1518.
125. Vedin, L.L.; Lewandowski, S.A.; Parini, P.; Gustafsson, J.A.; Steffensen, K.R. The oxysterol receptor LXR inhibits proliferation of human breast cancer cells. *Carcinogenesis* **2009**, *30*, 575–579.
126. Zelcer, N.; Hong, C.; Boyadjian, R.; Tontonoz, P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. *Science* **2009**, *325*, 100–104.

© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).